<DOC>
	<DOCNO>NCT02086734</DOCNO>
	<brief_summary>The purpose study evaluation dynamic contrast-enhanced CT ( Perfusion-CT ) therapeutic response predicition patient metastasize renal carcinoma ( mRCC ) undergo antiangiogenetic therapy ( AAT ) multikinase inhibitor . In study patient mRCC AAT examine 3 serial Perfusion - CT scan - partially intergrated regular stag CT scheme - baseline ( AAT start ) , 1 week AAT well 8 week AAT initialization . Thereby select intrabdomial intrathoracic metastasis monitor longitudinally perfusion CT. Pretreament post-treament perfusion characteristic assess metastatic lesion quantify correlated patient outcome .</brief_summary>
	<brief_title>Perfusion CT Predictor Response Antiangiogenic Therapy Patients With Metastasized Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Patients metastasize renal cell carcinoma treat Department Urology ( University Munich Grosshadern Campus ) 1 ) either Sunitinib ( Sutent® ) , Pazopanib ( Votrient ® ) bzw . Sorafenib ( Nexavar® ) firstline therapy 2 . ) Sunitinib ( Sutent® ) , Pazopanib ( Votrient ® ) bzw . Sorafenib ( Nexavar® ) secondline therapy fail firstline therapy , therapy least 2 week give informed consent participate study Patients : give informed consent know iodine allergy high grade renal insuffiency ( eGFR &lt; 30ml/min ) dialysis overt hyperthyreoidism singular metastasis &lt; 1cm diameter increase baseline creatine level &gt; 20 % CT examination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Perfusion-CT</keyword>
	<keyword>mRCC</keyword>
	<keyword>antiangiogenic therapy</keyword>
	<keyword>response assessment</keyword>
</DOC>